title: Hyperuricemia and Atrial Fibrillation.
abstract: The importance of atrial fibrillation (AF) as a cause of mortality and morbidity has prompted research on its pathogenesis and treatment. Recognition of AF risk factors is essential to prevent it and reduce the risk of death. Hyperuricemia has been widely accepted to be associated with the incidence of paroxysmal or persistent AF, as well as to the risk of AF in post cardiovascular surgery patients. The possible explanations for this association have been based on their relation with either oxidative stress or inflammation. To investigate the link between hyperuricemia and AF, it is necessary to refer to hyperuricemia-induced atrial remodeling. So far, both ionic channel and structural remodeling caused by hyperuricemia might be plausible explanations for the occurrence of AF. Inhibition of xanthine oxidase and nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase, or the use of antioxidants, along with serum uric acid (SUA) level reduction to prevent inflammation, might be useful. Uric acid transporters (UATs) play a key role in the regulation of intracellular uric acid concentration. Intracellular rather than serum uric acid level is considered more important for the pathogenesis of AF. Identification of UATs expressed in cells is thus important, and targeting UATs might become a potential strategy to reduce the risk of hyperuricemia-induced atrial fibrillation.
authors.affiliation: Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science.
authors.forename: Nani
authors.initials: N
authors.lastname: Maharani
authors.forename: Masanari
authors.initials: M
authors.lastname: Kuwabara
authors.forename: Ichiro
authors.initials: I
authors.lastname: Hisatome
mesh_terms: D000975:Antioxidants / Q000378:metabolism; D001281:Atrial Fibrillation / Q000097:blood / Q000209:etiology* / Q000517:prevention & control; D064752:Atrial Remodeling / Q000187:drug effects; D019317:Evidence-Based Medicine; D006801:Humans; D033461:Hyperuricemia / Q000097:blood / Q000150:complications* / Q000517:prevention & control; D007249:Inflammation / Q000150:complications; D018384:Oxidative Stress / Q000187:drug effects; D012307:Risk Factors; D014527:Uric Acid / Q000097:blood
chemical_list: D000975:Antioxidants; D014527:Uric Acid